### INVITED SPEAKER PRESENTATION



**Open Access** 

# Use of new resistance markers to predict virologic response to antiretrovirals

Mark A Wainberg<sup>\*</sup>, Thomas Toni, Bluma G Brenner

*From* 16<sup>th</sup> International Symposium on HIV and Emerging Infectious Diseases Marseille, France. 24-26 March 2010

#### Aim

There can now be little doubt that certain drug-resistance mutations are more likely to emerge in viruses of certain subtypes than others. Two of the best and most practical examples of this are the emergence of the V106M NNRTI mutation and the K65R NRTI mutation in viruses of subtype C.

#### Methods

It is relevant that the use of newer more sensitive methods have been key in establishing the role that certain drug-resistance mutations may play in both transmitted and acquired drug resistance. In particular, the use of allele-specific PCR assays (AS-PCR) and pyrosequencing have been very useful in providing new insights.

#### Results

Among the reasons that more ultrasensitive assays may sometimes be needed for more accurate assessments of drug resistance is the differential effect of certain mutations on viral replicative capacity. As an example, the K65R mutation is known to adversely affect HIV replication, and this may be one of the reasons that it is found relatively infrequently among individuals who fail antiretroviral therapy. In contrast, the use of AS-PCR for K65R in subtype C viruses has shown that this method was able to detect the presence of this mutation in an additional 4 of 30 samples who had tested negative by bulk sequencing methods. Now, it also appears as though the transmission of the K65R mutation, while rare, can also be detected in higher numbers by AS-PCR than bulk sequencing, and that this is also more common among subtype C than subtype B viruses. The likely reason is that subtype C viruses are more prone to develop K65R as a consequence of treatment failure

McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada H3T 1E2



#### Discussion

Thus, the reason that some resistance-associated mutations are not commonly observed in newly-infected subjects is not because they impact on the ability of HIV to be transmitted but rather because they may quickly revert to wild-type in the absence of drug pressure and then be rapidly overgrown by wild-type variants.

Published: 11 May 2010

doi:10.1186/1742-4690-7-S1-I21 Cite this article as: Wainberg *et al.*: Use of new resistance markers to predict virologic response to antiretrovirals. *Retrovirology* 2010 7(Suppl 1):121.

## Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

**BioMed** Central

Submit your manuscript at www.biomedcentral.com/submit

Bio Med Central © 2010 Wainberg et al; licensee BioMed Central Ltd.